ARF1 and non-small cell lung carcinoma: For example, the M-COPA (2-methylcoprophilinamide) compound, inhibiting Arf1 (ADP ribosylation factor 1) involved in COPI and clathrin-coated transport vesicles, has been shown to disrupt the Golgi apparatus and RTK translocation to the membrane, to have antitumor effects against MET-addicted gastric cancers, and to overcome TKI resistance in EGFR-mutated non-small-cell lung carcinoma [124,125].